Gilead Sciences (GILD) Stock Falls on Q4 2025 Earnings

Gilead Sciences (GILD) reported fourth-quarter 2025 results with revenue of $7.9 billion, up 4.7% year-over-year, and diluted earnings per share of $1.74, up 22.5% year-over-year.

Total revenue: $7.9 billion (+4.7% year-over-year).

Gross profit: $6.3 billion (+5.2% year-over-year).

Operating profit: $2.0 billion (-19.1% year-over-year).

Net income attributable to common shareholders: $2.2 billion (+22.4% year-over-year).

Diluted EPS: $1.74 (+22.5% year-over-year).

Other notable items from the quarter:

Cash from operating activities: $3.3 billion (declined 142.4% year-over-year).

Cash and cash equivalents: $7.3 billion (down 26.6% year-over-year).

Total liabilities: $36.4 billion (down 8.4% year-over-year).

Capital expenditures (purchases of property, plant and equipment): $205 million (up 39.5% year-over-year).

Cost of sales: $1.6 billion (+2.7% year-over-year).

Gilead’s revenue modestly beat the consensus revenue estimate of $7.85 billion, while reported EPS came in below the estimate of $1.85. Shares were down 5.78% since the market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Gilead Sciences Inc. Insider Trading Activity

Gilead Sciences Inc. insiders have traded $GILD stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.

Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:

DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 12 sales selling 291,280 shares for an estimated $40,316,816.
JOHANNA MERCIER (Chief Commercial Officer) has made 0 purchases and 12 sales selling 68,000 shares for an estimated $8,276,980.
DEBORAH H TELMAN (EVP, Corporate Affairs & GC) has made 0 purchases and 3 sales selling 53,646 shares for an estimated $6,590,487.
ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 16,000 shares for an estimated $1,927,455.
JEFFREY BLUESTONE has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,242,900.
KELLY A. KRAMER has made 0 purchases and 2 sales selling 5,611 shares for an estimated $713,186.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Gilead Sciences Inc. Hedge Fund Activity

We have seen 1,050 institutional investors add shares of Gilead Sciences Inc. stock to their portfolio, and 893 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP removed 11,911,976 shares (-31.7%) from their portfolio in Q3 2025, for an estimated $1,322,229,336
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 9,393,952 shares (+56.6%) to their portfolio in Q3 2025, for an estimated $1,042,728,672
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 4,113,999 shares (+3763.8%) to their portfolio in Q4 2025, for an estimated $504,952,237
PACER ADVISORS, INC. removed 3,590,745 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $440,728,041
ASSENAGON ASSET MANAGEMENT S.A. removed 3,222,008 shares (-92.3%) from their portfolio in Q4 2025, for an estimated $395,469,261
PRICE T ROWE ASSOCIATES INC /MD/ added 2,916,699 shares (+12.4%) to their portfolio in Q3 2025, for an estimated $323,753,589
AMUNDI removed 2,883,630 shares (-27.5%) from their portfolio in Q3 2025, for an estimated $320,082,930

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Gilead Sciences Inc. Government Contracts

We have seen $14,894 of award payments to $GILD over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

LENACAPAVIR (SUNLENCA): $14,894

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Gilead Sciences Inc. Congressional Stock Trading

Members of Congress have traded $GILD stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:

REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Gilead Sciences Inc. Analyst Ratings

Wall Street analysts have issued reports on $GILD in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 12/10/2025
Truist Securities issued a "Buy" rating on 11/24/2025
Needham issued a "Buy" rating on 11/13/2025
Scotiabank issued a "Sector Outperform" rating on 11/13/2025
JP Morgan issued a "Overweight" rating on 10/31/2025
TD Cowen issued a "Buy" rating on 10/23/2025
Citigroup issued a "Buy" rating on 10/08/2025

To track analyst ratings and price targets for Gilead Sciences Inc., check out Quiver Quantitative's $GILD forecast page.

Gilead Sciences Inc. Price Targets

Multiple analysts have issued price targets for $GILD recently. We have seen 12 analysts offer price targets for $GILD in the last 6 months, with a median target of $145.0.

Here are some recent targets:

Gregory Renza from Truist Securities set a target price of $145.0 on 01/27/2026
Geoff Meacham from Citigroup set a target price of $156.0 on 01/27/2026
Michael Yee from UBS set a target price of $155.0 on 01/26/2026
Matthew Harrison from Morgan Stanley set a target price of $150.0 on 01/13/2026
Mohit Bansal from Wells Fargo set a target price of $150.0 on 12/10/2025
Joseph Stringer from Needham set a target price of $140.0 on 11/13/2025
Louis Chen from Scotiabank set a target price of $140.0 on 11/13/2025